- Servier buys into muscular dystrophy with potentially $2.7B deal<figure><div><img src="https://imgproxy.divecdn.com/noY6Oanv5v-_yDQZKEqBBDkEKvecYGoj9vaCkgyW_q0/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjgxODMyMjUyX20yY…BioPharma Dive · 1mo ago↗ source
- 2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?<p>Orphan drugs remain commercially durable, strategically relevant and supported by a strong pipeline</p>BioPharma Dive · 1mo ago↗ source
- Akeso, Summit drug extends survival in closely watched lung cancer trial<figure><div><img src="https://imgproxy.divecdn.com/U1p_j9BDqJ48JLk77g8bxOnzXIh5YVNKqCXZdq4xNwI/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDcxMDQzNjg0LmpwZ…